Skip to content

XNCR

Xencor, Inc.

NASDAQ · USHealthcareBiotechnology
$18.81+7.67%

Price as of Jul 20, 2026

XNCR growth

Xencor, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
-29.2%
EBITDA
+13.0%
EBIT
-35.4%
EPS
+27.8%
Free cash flow
-7.9%
Operating cash flow
-12.9%

Forward estimates

Revenue
+32.5%
EBITDA
+89.5%
EPS
-28.1%

Three-year CAGR

Revenue
-8.6%
EBITDA
+74.8%
EBIT
+0.5%
Net income
+60.5%
EPS
+65.4%
Free cash flow
+33.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.